Literature DB >> 25899049

Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis.

Kichang Han1, Heung Kyu Ko2, Kyung Won Kim1, Hyung Jin Won1, Yong Moon Shin1, Pyo Nyun Kim1.   

Abstract

The purpose of this study was to perform a meta-analysis and systematic review of the clinical efficacy and safety of radiofrequency (RF) ablation in the treatment of intrahepatic cholangiocarcinoma (ICC). A comprehensive literature search of Ovid MEDLINE and EMBASE identified studies describing the use of RF ablation in the treatment of ICC. Data describing overall survival, local tumor progression, and complications were collected. Seven observational studies that comprised 84 patients were reviewed. The pooled 1-year, 3-year, and 5-year survival rates were 82% (95% confidence interval [CI], 72%-90%), 47% (95% CI, 28%-65%), and 24% (95% CI, 11%-40%). One or 2 major complications occurred in 4 studies, and 1 patient died of liver abscess and subsequent sepsis despite treatment with percutaneous drainage and antibiotics. RF ablation is a locoregional treatment option that prolongs survival rates in patients with ICC who are ineligible for surgery.
Copyright © 2015 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25899049     DOI: 10.1016/j.jvir.2015.02.024

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  30 in total

Review 1.  Ablative therapies for intrahepatic cholangiocarcinoma.

Authors:  Junichi Shindoh
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

Review 2.  Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?

Authors:  Eugene J Koay; Bruno C Odisio; Milind Javle; Jean-Nicolas Vauthey; Christopher H Crane
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

3.  Short- and Long-Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome.

Authors:  Christian Hobeika; François Cauchy; Nicolas Poté; Pierre-Emmanuel Rautou; François Durand; Olivier Farges; Safi Dokmak; Valérie Vilgrain; Maxime Ronot; Valérie Paradis; Olivier Soubrane
Journal:  World J Surg       Date:  2019-08       Impact factor: 3.352

Review 4.  The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma.

Authors:  Anna Maria Ierardi; Salvatore Alessio Angileri; Francesca Patella; Silvia Panella; Natalie Lucchina; Elena N Petre; Antonio Pinto; Giuseppe Franceschelli; Gianpaolo Carrafiello; Gianpaolo Cornalba; Constantinos T Sofocleous
Journal:  Med Oncol       Date:  2016-12-22       Impact factor: 3.064

Review 5.  Intrahepatic Cholangiocarcinoma.

Authors:  Pouya Entezari; Ahsun Riaz
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

Review 6.  Ablation of Intrahepatic Cholangiocarcinoma.

Authors:  Jennifer Sweeney; Nainesh Parikh; Ghassan El-Haddad; Bela Kis
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

Review 7.  Locoregional Therapies of Cholangiocarcinoma.

Authors:  Christof M Sommer; Hans U Kauczor; Philippe L Pereira
Journal:  Visc Med       Date:  2016-12-05

8.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

Review 9.  Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemic.

Authors:  S Bennett; K Søreide; S Gholami; P Pessaux; C Teh; E Segelov; H Kennecke; H Prenen; S Myrehaug; D Callegaro; J Hallet
Journal:  Curr Oncol       Date:  2020-10-01       Impact factor: 3.677

10.  Combination of intraoperative radiofrequency ablation and surgical resection for treatment of cholangiocarcinoma: feasibility and long-term survival.

Authors:  Sang Min Lee; Heung Kyu Ko; Ji Hoon Shin; Jin-Hyoung Kim; Hee Ho Chu
Journal:  Diagn Interv Radiol       Date:  2020-01       Impact factor: 2.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.